Alumis Inc. (ALMS) Spending and interest coverage
- R&D / revenue · 12 months: Value 4697.19%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 601.60%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 4697.19% | Research and development expense / revenue. Period ending 2026-06-30. $347.50M ÷ $7.40M × 100 ≈ 4697.19% |
| Stock-based compensation / revenue · 12 months | 601.60% | Share-based compensation / revenue. Period ending 2026-06-30. $44.51M ÷ $7.40M × 100 ≈ 601.60% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 347.50M USD | Research and Development Expense |
| Revenue | 7.40M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 44.51M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -459.00M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $347.50M | $7.40M | $44.51M | $-459.00M | (m) | 4697.19% | 601.60% | (m) | (m) |
| 2026-03-31 | $370.92M | $8.40M | $48.87M | $-450.69M | (m) | 4414.62% | 581.62% | (m) | (m) |
| 2025-12-31 | $386.00M | $24.05M | $43.52M | $-453.80M | (m) | 1604.98% | 180.97% | (m) | (m) |
| 2025-09-30 | $390.42M | (m) | $41.77M | $-455.98M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $380.40M | (m) | $39.30M | $-439.09M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $320.21M | (m) | $23.80M | $-354.69M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $265.55M | (m) | $19.46M | $-300.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $137.68M | (m) | $8.63M | $-158.17M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.